Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study

Autor: Sara Manti, Alessandro Giallongo, Giulia Pecora, Giuseppe F. Parisi, Maria Papale, Enza Mulè, Donatella Aloisio, Novella Rotolo, Salvatore Leonardi
Rok vydání: 2023
Předmět:
Zdroj: Pediatric Pulmonology. 58:1085-1091
ISSN: 1099-0496
8755-6863
Popis: Asthma guidelines have recommended to continue treatment with biologics during COVID-19 pandemic. However, continuation of treatment with biologics in patients with SARS-CoV-2 has been little investigated.To assess the safety of biologics in patients with SARS-CoV-2 infection.A pilot, monocentre, prospective study. Patients aged 12 years old and older with severe asthma on treatment with biologics and confirmed SARS-CoV-2 infection were enrolled. Patients were followed-up with periodic calls at different time points up to 3 months to detect any adverse effect and its relationship with biologic treatment according to the Naranjo Adverse Probability Scale (NAPS). Severity of SARS-CoV-2 infection and clinical outcome were also assessed.Overall, we included 21 patients (10 on therapy with omalizumab, 9 with dupilumab and 2 with mepolizumab). Only a patient reported 2 local adverse events. No other adverse event was reported. Twenty out of 21 patients had a mild COVID-19 course and no adverse outcome was observed.we showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS-CoV-2 infection, as the treatment did not result in adverse events or outcomes. This article is protected by copyright. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: